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Abstract 
 
Duchenne muscular dystrophy (DMD) is a lethal x-linked recessive disorder, characterised 
by progressive skeletal muscle weakness, accompanied by cardiac and smooth muscle 
dysfunction. Although the main cause of death in DMD used to be respiratory problems 
caused by deterioration of the diaphragm, developments in respiratory care means that 
cardiac failure is now the major cause of death, despite the introduction of cardio-protective 
treatment such as angiotensin-converting-enzyme inhibitors and beta-blockers. Once 
affected, the heart progressively deteriorates over time, with the main problem being due to 
the death of cardiomyocytes. A loss of dystrophin makes the sarcolemma more susceptible 
to damage, leading to an influx of calcium ions into the cell, activating proteases and 
ultimately resulting in cardiomyocyte death. The dead cells are replaced by fibrotic tissue 
which causes dilated cardiomyopathy. There is at present no cure for DMD, however there is 
much on-going research producing positive results based around the pathophysiology in 
DMD patients.   
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Introduction 
Muscular dystrophy is a group of inherited disorders that involve muscle weakness 
and the loss of muscle tissue through cycles of degeneration/regeneration, fibrosis 
and replacement of muscle with fatty tissue. Duchenne muscular dystrophy (DMD) 
and its milder variant Becker muscular dystrophy (BMD) result from mutations in the 
gene that encodes the 427-kDa cytoskeletal protein dystrophin (Johnson, 2002). 
Dystrophin is a rod-shaped protein responsible for connecting the extracellular matrix 
to the cytoskeleton of each muscle fibre via the dystrophin-associated complex 
(DGC), a protein complex at the muscle cell membrane (sarcolemma). Absence of 
dystrophin is associated with the loss of the DGC and structural weakness of the 
sarcolemma during contractile activity (Blake et al, 2002). DMD is a progressive and 
severe X-linked recessive muscle-wasting disease, with an incidence of 1 in every 
3500 male births (Beaudet et al, 2008). DMD is the most common muscular 
dystrophy in children, presenting in early childhood and characterised by proximal 
muscle weakness and calf hypertrophy in affected boys. Patients are usually 
confined to a wheelchair by the age of 12, with death occurring in their second or 
third decade. Most DMD mutations result in a complete lack of dystrophin, whereas 
mutations resulting in BMD tend to produce a functional, but truncated version of the 
dystrophin protein (Bushby et al, 2010). The incidence of BMD is less than DMD 
being 1 in 180 000 (Betancur et al, 2011). BMD is a milder form of the disease and 
has a later onset; patients can usually walk and have a much longer life span, 
although cardiac complications are very common in later life.  
 
Dystrophin 
The dystrophin gene is the largest described, spanning 2.5 megabases of the 
genomic sequence, accounting for 0.1% of the total human genome and is 
composed of 79 exons (Blake et al, 2002). Dystrophin is a rod-shaped protein, 
responsible for connecting the extracellular matrix to the cytoskeleton of each 
muscle fibre via a large protein complex containing many subunits (Johnson, 2002). 
Mutations in the dystrophin gene lead to a reduction in the stability of the cell 
membrane. Dystrophin is a cytosolic adapter protein, binding actin filaments to 
dystroglycan, an adhesion receptor (Berk et al, 2008). It is a member of the β-
spectrin/α-actinin protein family, characterised by an NH2-terminal actin binding 
domain followed by a variable number of repeating units. Dystrophin can be 
organised into four separate regions based on sequence homologies and protein 
binding capabilities. These are the actin-binding domain at the NH2 terminus, the 
central rod domain, the cysteine-rich domain and the COOH-terminal domain 
(Rando, 2001). The role of dystrophin is to link the cytoskeleton to the sarcolemma 
(Campbell, 1995). This link extends to the extracellular matrix via beta-dystroglycan 
interacting with alpha-dystroglycan, which binds extracellular matrix proteins 
including laminin alpha2, and proteoglycans: agrin and perlecan that possess laminin 
globular (LG) domains. The absence of dystrophin disrupts this link leading to 
compromised muscle sarcolemmal integrity (Bansal et al, 2011). The 
transmembrane segment of the dystroglycan β subunit associates with a complex of 
integral membrane proteins; its cytosolic domain binds dystrophin and other adapter 
proteins, as well as various intracellular signalling proteins. The resulting large, 
hererometric assemblage, the dystrophin glycoprotein complex (DGC) links the 
extracellular matrix to the cytoskeleton and signalling pathways within muscle and 
other types of cell (Campbell et al, 2000). Mutations in dystrophin can disrupt the 
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DGC-mediated link between the exterior and the interior of muscle cells, leading to 
muscular dystrophy.  
 
Cardiac involvement 
Cardiac failure is the major cause of death in DMD despite the introduction of cardio-
protective treatment such as angiotensin-converting-enzymes (ACE) inhibitors and 
beta-blockers (Ameen and Robson, 2010). DMD patients develop hypertrophic and 
dilated cardiomyopathy, which ultimately results in cardiac death in an increasing 
number of cases. Although present treatment options and frequent monitoring have 
led to vast improvements in the quality of life of DMD patients, their longer lifespan 
indicates that the cardiomyopathy that develops needs to be addressed. Signs of 
cardiac involvement have been found in 90% of DMD patients via the use of echo 
and electrocardiogram (ECG), with ECG abnormalities being detectable from as 
early as six years of age (Annane et al, 2010). Clinically apparent cardiomyopathy is 
first evident after 10 years of age, affects one-third of patients by the age of 14 years 
and is present in all patients over 18 years of age (Kornberg and Yiu, 2008). 
Preclinical cardiac involvement is seen in 25% of patients less than six years of age 
(Bain et al, 1990). Atrial and ventricular arrhythmias occur, including premature 
ventricular beats and more complex or sustained ventricular ectopy, which increases 
with age and ventricular dysfunction. Despite the high frequency of cardiac 
involvement, most patients are fairly asymptomatic due to physical inactivity (Cox 
and Kenkel, 1990). The occurrence of BMD patients in developing heart problems 
due to dilated cardiomyopathy is 70%, with heart failure being the primary cause of 
their death (Allen et al, 2009a; Finsterer and Stollberger, 2008).  ECG and echo 
changes have also been found in up to 90% of DMD and BMD carriers, with 7-11% 
developing dilated cardiomyopathy. This represents a major group of dystrophic 
patients for whom the heart is the major site of pathology.  
 
As with skeletal muscle, the absence of dystrophin results in the sarcolemma of 
cardiomyocytes becoming more susceptible to damage from muscle contractions. 
Allen and Williams (2007) found that stretch-activated ion channels do not open 
appropriately in dystrophin deficient cardiomyocytes when they are stretched during 
ventricular filling; this results in an increase in the influx of calcium into the cell. The 
tears in the membrane allow the entry of extracellular calcium, raising intracellular 
calcium levels. This leads to the activation of calcium-activated proteases, such as 
calcium induced Calpains, which destroy the plasma membranes, allowing even 
more calcium into the cell. Eventually the chronic calcium overload will result in the 
death of the cardiomyocyte.  
 
Cardiomyocyte death usually occurs in very discrete small areas of the heart known 
as microinfarcts (Lannaccone et al, 2003). Within these areas, cardiomyocyte death 
initiates an inflammatory cascade. Macrophages migrate into the heart to remove the 
damaged and dead cells. Fibroblasts subsequently invade the area and form 
fibrocollagenous scar tissue resulting in the deposition of fibrotic tissue in the walls of 
the heart, replacing the contractile cardiomyocyte (Allen et al, 2009b). As the fibrosis 
spreads, the ventricle thins and enlarges resulting in dilated cardiomyopathy in DMD 
and BMD patients.  
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Present treatment for DMD cardiomyopathy 
The standard therapy for DMD includes the use of glucocorticoids from the age of 
five or six. In addition present treatments using β adrenergic blockage and ACE 
inhibitors have proven to be effective at remodelling the heart (Bourke et al, 2003). 
ACE inhibitors block the conversion of angiotensin I to angiotensin II, which prevents 
the deposition of fibrotic material in the walls of the heart (Lawer et al, 1997). An 
uncontrolled retrospective study indicated that echocardiographic parameters, 
including fractional shortening, left ventricular ejection fraction and sphericity index in 
DMD and BMD patients improved three years after administration of ACE inhibitors 
alone and in combination with β-blockers (Belmont et al, 2005). A double-blind trial 
was conducted at the same time to assess the effect of preventative afterload 
reduction in muscular dystrophy patients. DMD patients between the ages of 9.5 and 
13 years with normal ventricular function were randomly chosen to receive three 
years of ACE inhibitor perindopril or a placebo. Following the three years each 
participant received perindopril for two years. A lower left ventricular fraction was 
found in the patients who did not receive perindopril for the first years (Bécane et al, 
2005). A later study by Coursey et al (2006) tested another ACE inhibitor called 
enalapril. Results showed that normalisation of fractional shortening occurred in 43% 
of patients taking enalapril; this improvement was maintained for up to four years. 
These two studies suggest that early pharmacological interventions are required and 
should be encouraged before cardiac symptoms are apparent in order to reserve 
cardiac function.  
New treatment options for muscular dystrophies and the heart 
There is at present no cure for either DMD or BMD; however there is a lot of on-
going research into these diseases. In the 1960s and 1970s there were few survivors 
of DMD beyond teenage years, but with developments in standards of patient care 
and disease management, lifespan has gradually extended (Baudouin et al, 2002). 
Pharmacological intervention has begun to change the natural history of DMD, with 
further advances and more effective treatment to target the underlying pathology of 
DMD.  
Corticosteroids 
The corticosteroids, deflazacort and prednisone, are currently the only evidence-
based effective treatments for DMD (Ashwal et al, 2005; Kuntzer et al, 2008). The 
exact cellular mechanisms responsible for corticosteroids’ beneficial effect are still 
unknown (Berket et al, 2010; Brooke et al, 2005). Despite this lack of knowledge of 
their action corticosteroids have been shown to slow the rate of disease progression 
and also extend functional abilities for two years or longer (Altman et al, 2012; 
Armaroli et al, 2012; Ashwal et al, 2005; Kuntzer et al, 2008). Improved pulmonary 
function, time to rise from supine to standing, time to climb four stairs and time to 
walk nine metres are all outcomes documenting the beneficial action of 
corticosteroids. Brooke et al (2001) found that glucocorticoid corticosteroids improve 
muscle strength and function in children with DMD treated from six months to two 
years as shown in randomized controlled clinical trials. Currently the most effective 
doses appear to be prednisone 0.75 mg/kg/day and deflazacort 0.9mg/Kg which 
appear to be equally effective in improving muscle strength and function in the short 
term (Ashwal et al, 2005). In nonrandomised trials, boys who were treated longer 
than two years with either prednisone or deflazacort showed significant benefits in  
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Table 1: Summary of current therapies for DMD 
Intervention Action/Effect 
Stem cell therapy Introduce dystrophin producing cells (Deutekom and 
Ommen, 2003). 
Myoblast transplantation Introduce dystrophin producing cells (Deutekom and 
Ommen, 2003).  
Corticosteroids Slows progression of muscle weakness, exact mechanism 
in DMD is unknown (Moxley et al, 2012). 
Myostatin inhibition Inhibit myostatin; a growth differentiation factor, that inhibits 
muscle differentiation and growth (Moxley et al, 2012). 
Utrophin upregulation Replacement of dystrophin (Deutekom and Ommen, 2003). 
Phosophodiesterase inhibitors Inhibit the inactivation of nitric oxide from the cGMP 
pathway to prevent contraction coupling damage (Moxley 
et al, 2012). 
Stop codon reading through Ribosomal read through of stop codons in mRNA to 
produce a full length protein. Ataluren and Gentamicin are 
examples (Lee et al, 2012).  
Exon Skipping  Removes specific exons from pre-mRNA to give a restored 
reading frame to produce a less severe phenotype, similar 
to BMD (Anthony et al, 2012).  
Gene therapy  Introduce mini-dystrophin into cells via a vector (adenoviral 
vectors) to replace depleted dystrophin (Duan and Zhang, 
2012) 
Nutritional E.g. the addition of gelatine, creatine and monohydrate 
may increase muscle protein synthesis by increasing ATP 
levels (Moxley et al, 2012).  
 
ambulation, delayed onset of scoliosis and pulmonary dysfunction, preserved cardiac 
function, survival and quality of life compared to untreated counterparts (Balaban et 
al, 2005; Altman et al, 2006; Hoyle et al, 2006). No clinically severe side effects have 
been observed in the short term studies performed with the use of corticosteroids, 
however, boys treated with corticosteroids for a mean time of 5.5 years were 
significantly shorter and had delayed puberty. Patients’ major concern with early 
corticosteroid treatment is with the effect on growth rate; however most feel that the 
benefits of the drug outweigh the risks (Altman et al, 2012; Armaroli et al, 2012). 
Side effects involving increased frequency of long bone fractures and vertebral 
fractures should be considered, although there is a lack of knowledge on how likely 
and severe these side effects are and what interventions are best to prevent or 
manage them (Armaroli et al, 2012). Despite the progress described above, further 
randomised trials are required to decide the optimal dose of steroids, the age to start 
taking corticosteroids and the prime dosing schedule to improve function with least 
side effects. In addition, long-term control studies will also be necessary to determine 
the long-term effects of corticosteroids on ambulation, bone, cardiac and respiratory 
function, behavioural problems and on patients’ quality of life. Uncontrolled studies of 
cohorts of DMD patients receiving prednisone or deflazacort for five years and longer 
have provided some encouraging results. Furthermore, Robert (2012) is performing 
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a large multicentre clinical trial to address the question of the optimal corticosteroid 
regimen for DMD and is recruiting patients this year.   
 
Stop codon read-through: gentamicin and ataluren 
Up to 20% of DMD patients have a premature stop codon (Ahn and Kunkel, 1993; 
Moxley et al, 2012). Aminoglycosides interfere with stop codons by introducing a 
nucleotide sequence at the aminoacyl transfer RNA acceptor site, allowing 
translation of mRNA into a protein of full length (Anderson et al, 1965; Davies et al, 
1964). Barton-Davis et al (1999) demonstrated that daily injections of gentamicin 
resulted in the production of a full-length dystrophin protein and a decrease in serum 
creatine levels. However trials in 2001 and 2003 showed less positive, varying 
results  with no dystrophin increase in the first trial and very little in the second 
(Burstein et al, 2001; Comi et al, 2003). Ataluren (PTC-124) is an oral 
nonaminoglyoside nonsense mutation suppressor, currently being used in clinical 
trials for both DMD and cystic fibrosis (Lee et al, 2012). In vitro, Ataluren is thought 
to be superior to gentamicin in terms of bioavailability (Almstead et al, 2007). Phase I 
and phase II trials have demonstrated an encouraging safety profile. However, the 
primary endpoint; a six minute walk test showed improvement, but not of statistical 
significance, so the study was completed early (Atkinson, 2011). Refinements have 
been made in the design of the study and current studies are recruiting 110 patients 
for a nine month trial, involving three daily doses (10, 10 and 20 mg/kg) for up to 36 
weeks (Barth, 2011), to establish Ataluren’s long-term safety.  
 
Exon skipping 
Antisense oligonucleotides (AOs) targeted to splicing elements within DMD pre-
mRNA can induce the skipping of targeted exons, restoring the open reading frame 
and the consequent production of a shorter but functional dystrophin protein. This 
results in a phenotype similar to BMD (Moxley et al, 2012). This treatment could be 
potentially beneficial to approximately 72% of DMD patients (Aartsma-Rus et al, 
2003). AOs are 20-30 nucleotides long and are complimentary in sequence to 
regions of the pre-mRNA transcript; they bind to specific sites on pre-mRNA to 
promote specific exon exclusion from the mature-mRNA. They can be delivered 
systemically or directly injected into muscle. Two AOs (Drisapersen and Etepliresen) 
currently show promise for targeting exon 51. Furthermore multiple intravenous AO 
trials in preclinical studies using canines resulted in functional improvement 
(Hoffman et al, 2009).  In 2007, four patients received an intramuscular dose of 
Drisapersen (Aartsma-Rus et al, 2007). Their muscle biopsies showed increased 
sarcolemma dystrophin expression, however functional improvement was not 
observed. Phase I or phase IIa studies were then carried out in which twelve patients 
received five weeks of subcutaneously injections. Results showed dystrophin 
expression in all twelve of the patients and ten out of the twelve patients 
demonstrated functional improvement in the 6 minute walk test. Although no serious 
adverse effects were documented, all treated patients developed proteinuria 
(Aartsma-Rus et al, 2011). A current phase III randomised, double blind and 
placebo-controlled clinical study aims to assess the safety and efficacy of 
Drisapersen in DMD patients (GlaxoSmithKline, 2011). Eteplirsen, also an AO that 
targets exon 5, is showing promising results. A study involving seven DMD patients 
receiving injections of Eteplirsen into the exterior digitorum brevis muscle (two 
patients received a dose of 0.09 mg, the other five 0.9 mg) produced a 44-79% 
increase in dystrophin positive fibres in the patients biopsies who received a dose of 
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0.9 mg (Anthony et al, 2012). A Phase II, open label, dose escalation study with  
systemic Eteplirsen showed that 7 of 19 patients had slight improvement with 
positive staining of sarcolemmal dystrophin, ranging from 8.9 to 16.4% (Abbs et al, 
2011). There was a dose-response effect and no side effects related to the drug.  
 
Gene therapy: Viral vectors 
The dystrophin gene consists of over 2.4M base pairs and is the largest human gene 
(Bertelson et al, 1987). Due to its large size, it is not possible to fit the entire gene 
into an adeno-associated virus, which is currently the best vehicle for gene transfer. 
The capacity for packing of the adeno-associated virus is 4.7 kb (Bourque et al, 
2002). Smaller versions of dystrophin (minidystrophin) have been developed to solve 
the problem of fitting the gene into the virus (Bourque et al, 2002; Bowles et al, 2010; 
Duan and Zhang, 2012). Studies have demonstrated that following their transfer 
there is protection of the plasma membrane of myofibers in adult mdx muscle (Li et 
al, 2000). The first clinical gene therapy trial in a study of six boys with frame-shift 
mutations was reported by Bowles et al (2010). A mini-dystrophin gene was 
delivered in an adeno-associated virus into one of the biceps muscle while the 
opposite bicep received saline. Muscle biopsy specimens were assessed on day 42, 
for four patients and day 90, for two patients. Vector DNA was detected in all 
patients, however functional protein was not visualised. Future studies are ongoing 
which include plans for systemic and regional intra-arterial delivery of a mini-
dystrophin gene contained within a vector. Immune reaction to viral vector transfer 
however still remains an important problem that needs addressing.  
 
P2X7 Receptor 
The lack of functional dystrophin in muscular dystrophy patients leads to raised 
levels of intracellular free calcium in the sub-sarcolemmal region of dystrophic 
muscle. Arkle et al (2006) have shown that dystrophin appears to have a function in 
controlling purinergic responses. In dystrophic (mdx) mouse myoblasts, a purinergic 
phenotype arises in which exposure to extracellular ATP triggers an increase in 
cytosolic Ca2+ which is primarily caused by activation of P2X7 receptors. P2X7 
receptors are a family of ionotrophic ATP-gated ion channels which are permeable to 
small cations including Ca2+.  ATP and other inflammatory mediators have been 
shown to up-regulate the expression and function of P2X7 receptors and they are 
now considered as a ‘danger’ sensor, detecting ATP where tissue damage occurs 
(Khakh and North, 2006). At an intracellular level the ATP content of muscles is high 
and ATP is released in small amounts in response to physiological muscle activity, 
acting through purinergic receptors to modulate skeletal muscle plasticity (Almarza et 
al, 2009). In muscular dystrophy patients, the fragility of myofibres results in large 
amounts of ATP being released into the extracellular space. It is possible that these 
high concentrations of ATP acting on the P2X7 receptor could contribute to DMD 
and BMD pathology by chronically increasing intracellular Ca2+ levels. Arkle et al 
(2012) have shown that P2X7 receptor expression and function are significantly 
altered in mouse dystrophic myoblasts and myotubes in vitro and ex vivo and also in 
mdx muscle in vivo. Pharmacological inhibition of this receptor in mdx mice in vivo 
resulted in a significantly lower number of relevant fibres in skeletal muscle, where 
such suppression indicates a reduced number of degeneration-regeneration cycles 
in treated animals (Davies et al, 2006). This suggests that treatment with P2X7 
antagonists may hinder the dystrophic process.  
 
The Plymouth Student Scientist, 2014, 7, (1), 201-215 
   
[208] 
 
P2X7 Receptor antagonists 
P2X7 receptor antagonists that have been identified in recent years include Brilliant 
Blue G (BBG), KN-62, PPADS and oATP (Donnell-Roberts and Jarvis, 2007). A 
feature shared between these antagonists is their differential affinity for human 
versus rodent P2X7 receptors (Chambers et al, 2007). KN-62 for example, potently 
blocks human P2X7 receptors, but is ineffective at the rat receptor (Humpreys et al, 
1998). Other antagonists such as oATP and PPADS show only weak affinity for 
blocking P2X7 receptors and have been found to be non-selective (Donnelly-Roberts 
and Jarvis, 2007). The inability of these antagonists to block rodent P2X7 receptors 
presents problems when determining the role of P2X7 modulation in experimental 
models. More recent, structurally distinct and competitive P2X7 receptor antagonists 
(A-740003 and A-438079) have been described, that show less species differences 
between humans and rats (Carroll et al, 2003). An even more recent study 
investigated a structurally novel, competitive P2X7 receptor antagonist, A-804598 
(Carroll et al, 2009). 
 
Conclusion 
In conclusion present treatment options and frequent monitoring have led to 
vast improvements in the quality of life of DMD patients. The longer lifespan 
however, has left DMD patients exposed to increased risk of cardiac 
problems. The cardiomyopathy that develops is a major health issue that 
needs to be addressed. The traditional view that medication should be started 
only when symptoms have become evident is being challenged. Treatments 
are now being initiated before symptoms are seen to help protect from heart 
damage. As the number of boys with DMD are surviving longer and 
developing cardiomyopathy, new treatment regimens are being examined to 
help treat cardiomyopathy and cure DMD altogether.  
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